2019
Clinical validation of reduction in cocaine frequency level as an endpoint in clinical trials for cocaine use disorder
Roos CR, Nich C, Mun CJ, Babuscio TA, Mendonca J, Miguel AQC, DeVito EE, Yip SW, Witkiewitz K, Carroll KM, Kiluk BD. Clinical validation of reduction in cocaine frequency level as an endpoint in clinical trials for cocaine use disorder. Drug And Alcohol Dependence 2019, 205: 107648. PMID: 31677490, PMCID: PMC6910212, DOI: 10.1016/j.drugalcdep.2019.107648.Peer-Reviewed Original Research
2016
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone
Roos CR, Mann K, Witkiewitz K. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. Addiction Biology 2016, 22: 1528-1539. PMID: 27480445, PMCID: PMC5290305, DOI: 10.1111/adb.12427.Peer-Reviewed Original ResearchMeSH KeywordsAcamprosateAdultAlcohol DeterrentsAlcohol DrinkingAlcoholismFemaleHumansMaleNaltrexoneNarcotic AntagonistsReproducibility of ResultsRewardTaurineTreatment OutcomeConceptsAlcohol use disorderTreatment of AUDOpioid receptor antagonistRandomized clinical trialsBetter drinking outcomesGlutamatergic systemSubtypes of individualsReceptor antagonistClinical trialsRewarding effectsUse disordersClinical decisionDrinking outcomesReward drinkersDrinkersNaltrexoneExcellent reliabilityDifferential benefitsDistinct patterns
2015
Reproducibility and differential item functioning of the alcohol dependence syndrome construct across four alcohol treatment studies: An integrative data analysis
Witkiewitz K, Hallgren KA, O'Sickey AJ, Roos CR, Maisto SA. Reproducibility and differential item functioning of the alcohol dependence syndrome construct across four alcohol treatment studies: An integrative data analysis. Drug And Alcohol Dependence 2015, 158: 86-93. PMID: 26613839, PMCID: PMC4698096, DOI: 10.1016/j.drugalcdep.2015.11.001.Peer-Reviewed Original Research